Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of Directors
Rhea-AI Summary
Inspire Medical Systems (NYSE: INSP), a medical technology company focused on minimally invasive treatments for obstructive sleep apnea (OSA), appointed seasoned medical device executive Michael H. Carrel to its Board of Directors, effective July 20. Chairman and CEO Tim Herbert said the company looks forward to his guidance as it advances Inspire therapy.
Carrel has served as President, Chief Executive Officer and director of AtriCure (NASDAQ: ATRC) since November 2012. Under his leadership, AtriCure’s revenue grew from $82 million in 2013 to $535 million in 2025, treating more than one million patients. He previously chaired the board of Axonics from 2019 to 2024, through its sale to Boston Scientific. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School. He cited Inspire’s fifth-generation device, product pipeline and growing evidence of long-term cardiovascular benefits as reasons he believes the company is well positioned to expand access for OSA patients.
Positive
- Board strengthened with experienced operator Michael H. Carrel joins as director, bringing long-tenured CEO and board experience at medical device companies.
- AtriCure revenue track record grew from $82 million in 2013 to $535 million in 2025 under Carrel’s leadership, alongside treatment of over one million patients.
Negative
- None.
News Market Reaction – INSP
In the Jul 27 session, INSP gained 3.54%, reflecting a moderate positive market reaction. Argus tracked a trough of -7.2% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Board appointment adds proven medical device leadership
MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of seasoned medical device executive Michael H. Carrel to its Board of Directors effective July 20.
“We are pleased to welcome Mr. Carrel to our Board of Directors,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “Mike brings extensive executive leadership, board and medical device experience, including a strong track record of developing and commercializing minimally invasive therapies, and we look forward to his guidance as we continue advancing Inspire therapy for the many patients affected by OSA.”
Mr. Carrel has served as President, Chief Executive Officer, and a director of AtriCure, Inc. (NASDAQ: ATRC), an innovative cardiac device company, since November 2012. Under Mr. Carrel’s leadership, AtriCure has advanced a robust pipeline of novel products for the treatment of atrial fibrillation, left atrial appendage management and pain management. During his tenure, AtriCure has grown from
Previously, Mr. Carrel served as Chairman of the Board of Directors of Axonics, Inc. from 2019 through 2024, until its sale to Boston Scientific Corporation. Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School of the University of Pennsylvania.
“I am excited to join Inspire at this important stage in the Company’s growth,” said Mr. Carrel. “With the recent launch of the fifth-generation Inspire device, a compelling product pipeline and a growing body of evidence demonstrating the long-term benefits of Inspire therapy, particularly in cardiovascular health, I believe the Company is well positioned to continue expanding access to care for patients with OSA.”
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA-, EU MDR- and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
